- Home
- EB vs ITOS Comparison
EB vs ITOS Comparison
Compare EB & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EB
- ITOS
- Stock Information
- Founded
- EB 2008
- ITOS 2011
- Country
- EB United States
- ITOS United States
- Employees
- EB N/A
- ITOS N/A
- Industry
- EB EDP Services
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EB Technology
- ITOS Health Care
- Exchange
- EB Nasdaq
- ITOS Nasdaq
- Market Cap
- EB 324.6M
- ITOS 270.7M
- IPO Year
- EB 2018
- ITOS 2020
- Fundamental
- Price
- EB $3.26
- ITOS $7.41
- Analyst Decision
- EB Buy
- ITOS Strong Buy
- Analyst Count
- EB 6
- ITOS 3
- Target Price
- EB $6.70
- ITOS $21.33
- AVG Volume (30 Days)
- EB 692.7K
- ITOS 205.1K
- Earning Date
- EB 02-27-2025
- ITOS 03-05-2025
- Dividend Yield
- EB N/A
- ITOS N/A
- EPS Growth
- EB N/A
- ITOS N/A
- EPS
- EB N/A
- ITOS N/A
- Revenue
- EB $336,368,000.00
- ITOS $35,000,000.00
- Revenue This Year
- EB $2.57
- ITOS $271.18
- Revenue Next Year
- EB $4.11
- ITOS N/A
- P/E Ratio
- EB N/A
- ITOS N/A
- Revenue Growth
- EB 8.54
- ITOS N/A
- 52 Week Low
- EB $2.51
- ITOS $7.06
- 52 Week High
- EB $8.46
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- EB 43.47
- ITOS 45.45
- Support Level
- EB $3.32
- ITOS $7.06
- Resistance Level
- EB $3.41
- ITOS $7.61
- Average True Range (ATR)
- EB 0.15
- ITOS 0.25
- MACD
- EB -0.00
- ITOS 0.01
- Stochastic Oscillator
- EB 43.40
- ITOS 40.23
About EB Eventbrite Inc.
Eventbrite Inc is a self-service ticketing and experience technology platform that serves event creators. It is engaged in creating a platform to enable creators to solve many challenges associated with creating live experiences. The Company's platform integrates components needed to seamlessly plan, promote and produce live events. Its platform helps to plan, promote and produce live events, thereby allowing creators to reduce friction and costs, increase reach and drive ticket sales. Geographically, it generates maximum revenue from the United States.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.